Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
NCT01340235Phase 3Unknown
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jun 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of erythromycin in epidermolysis bullosa simplex (EBS), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Number of patients with decrease of blisters' number of at least 20% at 3 months. Status: unknown.
02
Drugs
erythromycin
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on NCT01340235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01340235.